Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Rom J Intern Med ; 52(3): 183-8, 2014.
Article in English | MEDLINE | ID: mdl-25509563

ABSTRACT

Stress is considered a risk factor for the irritable bowel syndrome (IBS). One of the main stress sources is represented by the negative life events and trauma suffered in childhood. Several papers have endorsed the hypothesis that youth submitted to stress are prone to develop IBS. We have undertaken a review of the literature, searching all Pubmed papers pertinent to child abuse and IBS. The data suggest that indeed, children submitted to physical, psychological and sexual abuse are at risk to develop IBS as adults. However, cultural diffferences exist.


Subject(s)
Child Abuse/psychology , Irritable Bowel Syndrome/epidemiology , Irritable Bowel Syndrome/psychology , Stress, Psychological , Adult , Anxiety Disorders , Child , Humans , Neuroticism , Risk Factors , Stress Disorders, Post-Traumatic/epidemiology
2.
Rom J Intern Med ; 50(1): 3-6, 2012.
Article in English | MEDLINE | ID: mdl-22788087

ABSTRACT

The inflammation is an important component of the bowel wall structure. The amount of inflammation is gradually increased from normal state, to functional bowel disorders and to inflammatory bowel disease. Calprotectin is a recently established marker for intestinal inflammation. This paper surveys the present knowledge on fecal calprotectin testing as predictor of intestinal inflammation. We also show on a sample of patients that inflammation as tested with fecal calprotectin test may also be found, in lower degree, in irritable bowel syndrome. In inflammatory bowel disease, the calprotectin fecal test shows higher intensity values.


Subject(s)
Feces/chemistry , Inflammatory Bowel Diseases/diagnosis , Irritable Bowel Syndrome/diagnosis , Leukocyte L1 Antigen Complex/analysis , Biomarkers/analysis , Diagnosis, Differential , Humans , Interleukin-8/analysis , Mast Cells , Serotonin/analysis
5.
Am J Med ; 82(6B): 59-64, 1987 Jun 26.
Article in English | MEDLINE | ID: mdl-3300312

ABSTRACT

In a multiclinic, randomized trial, oral norfloxacin, a fluoroquinolone antibacterial, was compared with several standard parenteral regimens for the treatment of nonbacteremic, hospital-acquired urinary tract infections. Parenteral antibiotic agents included aminoglycosides alone; aminoglycosides in combination with either broad-spectrum penicillins or first-generation cephalosporins; or cefotaxime alone. Ninety-two percent of bacterial isolates were multiresistant gram-negative rods including Pseudomonas aeruginosa (31 percent), Escherichia coli (17 percent), Klebsiella/Enterobacter species (14 percent), and Serratia species (11 percent). In the first evaluable 94 patients, norfloxacin was comparable to the parenteral agents in eliminating infecting bacteria from the urine. Similarly, combined bacterial eradication and clinical cure or improvement occurred in 96 percent (76 percent with cures, 20 percent with improvement) of those treated with norfloxacin and 88 percent (67 percent with cures, 21 percent with improvement) of those treated with parenteral agents. A negative outcome (i.e., failure, superinfection, or reinfection) occurred in two (4 percent) norfloxacin-treated patients versus six (12 percent) parenterally treated patients. Adverse effects were few, infrequently drug related, and rarely serious (one with norfloxacin versus two with parenteral agents). Additionally, drug, preparation, and administration costs were substantially less with oral norfloxacin compared with the parenteral agents. The data suggest, therefore, that oral norfloxacin can be substituted for commonly used parenteral antibiotic regimens, without any compromise in efficacy, in the treatment of nonbacteremic patients with multiresistant, nosocomial urinary tract infections.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Cross Infection/drug therapy , Norfloxacin/therapeutic use , Urinary Tract Infections/drug therapy , Adult , Aged , Aged, 80 and over , Aminoglycosides/therapeutic use , Anti-Bacterial Agents/adverse effects , Clinical Trials as Topic , Female , Humans , Lactams , Male , Middle Aged , Norfloxacin/adverse effects , Opportunistic Infections/etiology , Random Allocation , Vancomycin/therapeutic use
6.
Am J Med ; 82(6B): 70-4, 1987 Jun 26.
Article in English | MEDLINE | ID: mdl-3300314

ABSTRACT

A retrospective analysis of data from the treatment of 95 men with nonbacteremic urinary tract infections (UTIs) (clean-catch urinary bacterial count greater than or equal to 10(5) colony-forming units/ml) who received norfloxacin (400 mg orally twice daily) was performed. Treatment duration ranged from a required minimum of seven days to a maximum of 30 days. If an underlying anatomic or functional condition existed that might decrease the likelihood of a favorable medical response and/or require prolonged treatment, the patient's UTI was considered "complicated." In addition to eight patients with polymicrobic UTIs (usually involving enterococci or Pseudomonas aeruginosa), 48 men (i.e., 51 percent of the total population) had an identifiable complication. Complications included benign prostatic hypertrophy in 13 patients; prostatic cancer in four; urethral stricture in four; quadriplegia/paraplegia with indwelling urinary catheter in four; prostatism in three; and other conditions commonly recognized as altering the response to antibiotic treatment. Among the 95 patients treated, 76 (80 percent) were considered to have had a cure and five (5 percent) showed improvement. Fourteen patients (15 percent) failed to show a response to treatment. Of the 48 patients with UTI and defined complications, 36 (75 percent) had a cure, three (6 percent) showed improvement, and therapy failed in nine (19 percent). Ninety-seven percent (105 of 108) of the pretreatment bacterial isolates were susceptible to norfloxacin. In addition to the three resistant organisms that were present prior to therapy, three organisms (two P. aeruginosa and one Enterobacter) persisted and acquired resistance during therapy. Five adverse clinical experiences and six adverse laboratory experiences were noted. Only one of the former (mild heartburn) was thought to be drug related, and no adverse experience was considered serious or required discontinuation of treatment. Gastrointestinal tolerability of oral norfloxacin was good.


Subject(s)
Norfloxacin/therapeutic use , Urinary Tract Infections/drug therapy , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Clinical Trials as Topic , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Norfloxacin/adverse effects , Prostatic Diseases/complications , Retrospective Studies , Spinal Cord Injuries/complications , Urinary Tract Infections/complications , Urinary Tract Infections/microbiology
7.
Eur J Clin Microbiol ; 3(5): 478-87, 1984 Oct.
Article in English | MEDLINE | ID: mdl-6389126

ABSTRACT

The efficacy, safety and tolerance of imipenem/cilastatin and moxalactam were compared in a randomized trial in the United States involving 19 centers and 441 patients. Significantly more organisms were susceptible to imipenem than moxalactam. Although the bacteriological outcomes were similar, the clinical outcome was significantly better in the imipenem/cilastatin treatment group. The incidence of colonization and superinfection was similar in both groups. Moxalactam was less irritating at the site of injection than imipenem/cilastatin. The safety profiles were similar except for bleeding episodes in the moxalactam group.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacteria/drug effects , Cyclopropanes/therapeutic use , Moxalactam/therapeutic use , Thienamycins/therapeutic use , Adult , Anti-Bacterial Agents/adverse effects , Anti-Bacterial Agents/pharmacology , Bacterial Infections/drug therapy , Cilastatin , Clinical Trials as Topic , Cyclopropanes/adverse effects , Cyclopropanes/pharmacology , Drug Combinations , Drug Tolerance , Female , Humans , Imipenem , Male , Microbial Sensitivity Tests , Middle Aged , Moxalactam/adverse effects , Moxalactam/pharmacology , Thienamycins/adverse effects , Thienamycins/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...